Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week open-label safety study of tralokinumab in Japanese adults and adolescents with uncontrolled asthma
jRCT2080223351Phase 3
- Sponsor
- AstraZeneca
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tralokinumab in asthma, sponsored by AstraZeneca.
02
Drugs
tralokinumab
03
Conditions
asthma
Beyond the preview
Go deeper on jRCT2080223351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223351.